Falcon Point Capital’s Corcept Therapeutics CORT Stock Holding History

Falcon Point Capital’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-31,620	Closed	-$230K	–	119
2016 Q4	$230K	Sell	31,620 -82,659	-72%	-$648K	0.03%	104
2016 Q3	$793K	Buy	114,279 +17,704	+18%	+$103K	0.12%	78
2016 Q2	$527K	Buy	96,575 +10,569	+12%	+$55K	0.09%	87
2016 Q1	$403K	Buy	86,006 +9,604	+13%	+$37.4K	0.07%	94
2015 Q4	$380K	Buy	76,402 +5,096	+7%	+$23K	0.08%	94
2015 Q3	$268K	Buy	+71,306	New	+$362K	0.1%	110

Other funds holding CORT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Falcon Point Capital's CORT Position: Q1 2017 in Review

Falcon Point Capital sold out of Corcept Therapeutics (CORT) in Q1 2017, closing a stake of 31,620 shares — an estimated $230K sold.

Falcon Point Capital first reported a position in CORT in Q3 2015 and held it in 6 quarters. The position peaked at $793K in Q3 2016. 135 funds tracked by Wall St. Rank hold CORT as of Q1 2017.

Falcon Point Capital reported no remaining Corcept Therapeutics position as of Q1 2017 after selling out during the quarter.
Falcon Point Capital sold 31,620 Corcept Therapeutics shares in Q1 2017, an estimated $230K.
Falcon Point Capital first reported a position in Corcept Therapeutics in Q3 2015 and held it in 6 quarters.
Falcon Point Capital's Corcept Therapeutics position peaked at $793K in Q3 2016.
135 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2017.

Based on Falcon Point Capital's 13F filing for Q1 2017, filed 2 May 2017.